Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan

被引:32
|
作者
Gaglio, Paul [1 ,2 ]
Marfo, Kwaku [1 ,2 ]
Chiodo, Joseph, III [3 ]
机构
[1] Montefiore Med Ctr, Div Hepatol, Bronx, NY 10467 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Otsuka Amer Pharmaceut Inc, Med Sci Liaison, Rockville, MD USA
关键词
Arginine vasopressin; MELD score; Portal hypertension; Vasopressin receptor antagonists; SERUM SODIUM CONCENTRATION; V-2 RECEPTOR ANTAGONIST; PRETRANSPLANT HYPONATREMIA; HEPATIC-ENCEPHALOPATHY; RISK-FACTORS; ASCITES; MULTICENTER; SATAVAPTAN; CONIVAPTAN; MANAGEMENT;
D O I
10.1007/s10620-012-2276-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hyponatremia is common in patients with cirrhosis and portal hypertension, and is characterized by excessive renal retention of water relative to sodium due to reduced solute-free water clearance. The primary cause is increased release of arginine vasopressin. Hyponatremia is associated with increased mortality in cirrhotic patients, those with end-stage liver disease (ESLD) on transplant waiting lists, and, in some studies, posttransplantation patients. Clinical evidence suggests that adding serum sodium to model for ESLD (MELD) scoring identifies patients in greatest need of liver transplantation by improving waiting list mortality prediction. Hyponatremia is also associated with numerous complications in liver disease patients, including severe ascites, hepatic encephalopathy, infectious complications, renal impairment, increased severity of liver disease in cirrhosis, and increased hospital stay and neurologic/infectious complications posttransplant. Vasopressin receptor antagonists, which act to increase free water excretion (aquaresis) and thereby increase serum sodium concentration, have been evaluated in patients with hypervolemic hyponatremia (including cirrhosis and heart failure) and euvolemic hyponatremia (SIADH). Tolvaptan, a selective vasopressin V-2-receptor antagonist, is the only oral agent in this class approved for raising sodium levels in hypervolemic and euvolemic hyponatremia. The SALT trials showed that tolvaptan treatment rapidly and effectively resolved hyponatremia in these settings, including cirrhosis, and it has been shown that this agent can be safely and effectively used in long-term treatment. Fluid restriction should be avoided during the first 24 h of treatment to prevent overly rapid correction of hyponatremia, and tolvaptan should not be used in patients who cannot sense/respond to thirst, anuric patients, hypovolemic patients, and/or those requiring urgent intervention to raise serum sodium acutely.
引用
收藏
页码:2774 / 2785
页数:12
相关论文
共 50 条
  • [41] Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia
    Ghali, Jalal K.
    Zmily, Hammam D.
    Farah, Jareer O.
    Daifallah, Suleiman
    IDRUGS, 2010, 13 (11) : 782 - 792
  • [42] Acute effects of vasopressin V2-receptor antagonist on kidney AQP2 expression and subcellular distribution
    Christensen, BM
    Marples, D
    Jensen, UB
    Frokiaer, J
    Sheikh-Hamad, D
    Knepper, M
    Nielsen, S
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1998, 275 (02) : F285 - F297
  • [43] PERITONEAL DIALYSIS FOR PATIENTS WITH END-STAGE RENAL DISEASE AND LIVER CIRRHOSIS
    Khan, Sana
    Rosner, Mitchell H.
    PERITONEAL DIALYSIS INTERNATIONAL, 2018, 38 (06): : 397 - 401
  • [44] THE TREATMENT OF END-STAGE LIVER-DISEASE IN CHILDHOOD
    SHEPHERD, RW
    AUSTRALIAN PAEDIATRIC JOURNAL, 1988, 24 (04): : 213 - 216
  • [45] Use of Oral Vasopressin V2 Receptor Antagonist for Hyponatremia in Acute Brain Injury
    Jeon, Sang-Beom
    Choi, H. Alex
    Lesch, Christine
    Kim, Myung Chun
    Badjatia, Neeraj
    Claassen, Jan
    Mayer, Stephan A.
    Lee, Kiwon
    EUROPEAN NEUROLOGY, 2013, 70 (3-4) : 142 - 148
  • [46] Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan
    Kramers, Bart J.
    van Gastel, Maatje D. A.
    Boertien, Wendy E.
    Meijer, Esther
    Gansevoort, Ron T.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 73 (03) : 354 - 362
  • [47] Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with Satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist
    Soupart, Alain
    Gross, Peter
    Legros, Jean-Jacques
    Alfoldi, Sandor
    Annane, Djillali
    Heshmati, Hassan M.
    Decaux, Guy
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (06): : 1154 - 1160
  • [48] Identification and synthesis of major metabolites of vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan®
    Molinari, Albert J.
    Trybulski, Eugene J.
    Bagli, Jehan
    Croce, Susan
    Considine, John
    Qi, Jian
    All, Kadum
    DeMaio, William
    Lihotz, Lynne
    Cochran, David
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (21) : 5796 - 5800
  • [49] Multivariate analyses for hepatic cirrhosis and evaluation of the model for end-stage liver disease
    Wen, Zhuofu
    Lin, Jing-Hua
    Zheng, Fengping
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 : A216 - A216
  • [50] Comparison of four models for end-stage liver disease in evaluating the prognosis of cirrhosis
    Jiang, Ming
    Liu, Fei
    Xiong, Wu-Jun
    Zhong, Lan
    Chen, Xi-Mei
    WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (42) : 6546 - 6550